KRASG12C IN-16
KRASG12C IN-16 (Compound SK-17) is a selective, covalent and an orally active KRASG12C inhibitor. KRASG12C IN-16 induces Apoptosis. KRASG12C IN-16 effectively prevents the activation of MAPK and PI3K/mTOR signaling pathways. KRASG12C IN-16 displays anti-tumor activity against pancreatic cancer[1].
Product Specifications
UNSPSC
12352005
Target
Apoptosis; mTOR; p38 MAPK; PI3K; Ras
Related Pathways
Apoptosis; GPCR/G Protein; MAPK/ERK Pathway; PI3K/Akt/mTOR
Field of Research
Cancer
Smiles
ClC1=C(C(NC(N2CC3=NC(N4CC(C4)N(C)C)=NC(N5C6CN(CC5CC6)C(C=C)=O)=C3C2)=O)=CC=C1)C
Molecular Formula
C28H35ClN8O2
Molecular Weight
551.08
References & Citations
[1]Fu S, et al. Design, Synthesis and Biological Evaluation of Pyrrolopyrimidine Urea Derivatives as Novel Krasg12c Inhibitors for the Treatment of Cancer.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
K-Ras
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
